This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vilchez, R. A.
Right arrow Articles by Butel, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vilchez, R. A.
Right arrow Articles by Butel, J. S.

Next Article 

Clinical Microbiology Reviews, July 2004, p. 495-508, Vol. 17, No. 3
0893-8512/04/$08.00+0     DOI: 10.1128/CMR.17.3.495-508.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Emergent Human Pathogen Simian Virus 40 and Its Role in Cancer

Regis A. Vilchez1,2 and Janet S. Butel2*

Departments of Medicine and,1 Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas2

The polyomavirus simian virus 40 (SV40) is a known oncogenic DNA virus which induces primary brain and bone cancers, malignant mesothelioma, and lymphomas in laboratory animals. Persuasive evidence now indicates that SV40 is causing infections in humans today and represents an emerging pathogen. A meta-analysis of molecular, pathological, and clinical data from 1,793 cancer patients indicates that there is a significant excess risk of SV40 associated with human primary brain cancers, primary bone cancers, malignant mesothelioma, and non-Hodgkin's lymphoma. Experimental data strongly suggest that SV40 may be functionally important in the development of some of those human malignancies. Therefore, the major types of tumors induced by SV40 in laboratory animals are the same as those human malignancies found to contain SV40 markers. The Institute of Medicine recently concluded that "the biological evidence is of moderate strength that SV40 exposure could lead to cancer in humans under natural conditions." This review analyzes the accumulating data that indicate that SV40 is a pathogen which has a possible etiologic role in human malignancies. Future research directions are considered.

* Corresponding author. Mailing address: Department of Molecular Virology and Microbiology, Baylor College of Medicine, Mail Stop BCM-385, One Baylor Plaza, Houston, TX 77030. Phone: (713) 798-3003. Fax: (713) 798-5019. E-mail: jbutel{at}bcm.tmc.edu.

Clinical Microbiology Reviews, July 2004, p. 495-508, Vol. 17, No. 3
0893-8512/04/$08.00+0     DOI: 10.1128/CMR.17.3.495-508.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • White, M. K., Safak, M., Khalili, K. (2009). Regulation of Gene Expression in Primate Polyomaviruses. J. Virol. 83: 10846-10856 [Abstract] [Full Text]  
  • Henzi, T., Blum, W.-V., Pfefferli, M., Kawecki, T. J., Salicio, V., Schwaller, B. (2009). SV40-Induced Expression of Calretinin Protects Mesothelial Cells from Asbestos Cytotoxicity and May Be a Key Factor Contributing to Mesothelioma Pathogenesis. Am. J. Pathol. 174: 2324-2336 [Abstract] [Full Text]  
  • Sroller, V., Vilchez, R. A., Stewart, A. R., Wong, C., Butel, J. S. (2008). Influence of the Viral Regulatory Region on Tumor Induction by Simian Virus 40 in Hamsters. J. Virol. 82: 871-879 [Abstract] [Full Text]  
  • Campanero-Rhodes, M. A., Smith, A., Chai, W., Sonnino, S., Mauri, L., Childs, R. A., Zhang, Y., Ewers, H., Helenius, A., Imberty, A., Feizi, T. (2007). N-Glycolyl GM1 Ganglioside as a Receptor for Simian Virus 40. J. Virol. 81: 12846-12858 [Abstract] [Full Text]  
  • Comar, M., Rizzardi, C., de Zotti, R., Melato, M., Bovenzi, M., Butel, J. S., Campello, C. (2007). SV40 Multiple Tissue Infection and Asbestos Exposure in a Hyperendemic Area for Malignant Mesothelioma. Cancer Res. 67: 8456-8459 [Abstract] [Full Text]  
  • Sterman, D. H., Recio, A., Carroll, R. G., Gillespie, C. T., Haas, A., Vachani, A., Kapoor, V., Sun, J., Hodinka, R., Brown, J. L., Corbley, M. J., Parr, M., Ho, M., Pastan, I., Machuzak, M., Benedict, W., Zhang, X.-q., Lord, E. M., Litzky, L. A., Heitjan, D. F., June, C. H., Kaiser, L. R., Vonderheide, R. H., Albelda, S. M. (2007). A Phase I Clinical Trial of Single-Dose Intrapleural IFN-{beta} Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses. Clin. Cancer Res. 13: 4456-4466 [Abstract] [Full Text]  
  • Marciniak, R. A., Cavazos, D., Montellano, R., Chen, Q., Guarente, L., Johnson, F. B. (2005). A Novel Telomere Structure in a Human Alternative Lengthening of Telomeres Cell Line. Cancer Res. 65: 2730-2737 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»